B. Pothuri

BNT323-01: A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
20260 citationsauthor #6
Results from the first-in-human phase 1 study of LY4170156, a folate receptor alpha-targeting antibody drug conjugate, in ovarian cancer patients previously exposed to antibody drug conjugate therapy
20260 citationsauthor #4
Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study
20252 citationsauthor #17
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
20251 citationsauthor #14
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2).
20251 citationsauthor #19
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
20250 citationsauthor #2
Minimal Required Data Set For Gynecological Cancer Trials: The GCIG Statement From The Barcelona Meeting
20250 citationsauthor #11
Identifying and breaking barriers for the treatment of gynecologic malignancies within the lesbian, gay, bisexual, transgender, queer/questioning, intersex and/or asexual community
20250 citationsauthor #1
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment.
20251 citationsauthor #8
ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
20250 citationsauthor #8
Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191].
20250 citationsauthor #7
Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies.
20255 citationsauthor #3
Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FRα), in advanced ovarian cancer and other solid tumors.
20251 citationsauthor #3
Accelerating breakthroughs: How a clinical trial fast-track program expands access to critical cancer treatments
20250 citationsauthor #8
Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up
20251 citationsauthor #10
Folate Receptor Alpha (FRα) Prevalence In Platinum Resistant Ovarian Cancer From Phase 1 Studies Of The Novel Antibody Drug Conjugate, Luveltamab Tazevibulin
20250 citationsauthor #6
Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers
20251 citationsauthor #1
Post hoc tipping point and multiple imputation analyses to determine the impact of early censored patients in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
20250 citationsauthor #1
Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US
20250 citationsauthor #9
Assessing disparities in real-world overall survival (rwOS) among sociodemographic groups in advanced ovarian cancer (aOC): The impact of biomarker testing and first-line (1L) maintenance therapies (mtx).
20250 citationsauthor #1
Differences in the molecular profiles of endometrial cancers between White and Black women: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
20250 citationsauthor #6
Identifying and breaking racial and ethnic barriers: Enhancing access and equity in the care of patients with gynecologic malignancies
20250 citationsauthor #1
Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
20250 citationsauthor #3
Concordance and frequency of TP53 protein expression and gene sequence in mismatch repair proficient (pMMR) and POLE wild-type endometrial cancer: An endometrial cancer molecularly targeted therapy consortium (ECMT2) database study
20250 citationsauthor #18
A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)
20250 citationsauthor #21
PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY
20250 citationsauthor #24
RACIAL SUBGROUP ANALYSES OF TUMOR RESPONSE AND SAFETY IN PATIENTS WITH MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH ADVANCED/RECURRENT ENDOMETRIAL CANCER RECEIVING DOSTARLIMAB MONOTHERAPY IN THE GARNET TRIAL
20250 citationsauthor #3
DB-1305/BNT325, a novel trophoblast cell-surface antigen 2 antibody-drug conjugate, in patients with ovarian cancer: Efficacy and safety data from a phase I/II study
20251 citationsauthor #2
Missed opportunities: Germline testing following tumor sequencing.
20250 citationsauthor #3
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.
20251 citationsauthor #14
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
20250 citationsauthor #19
HER2 expression in an endometrial cancer cohort.
20253 citationsauthor #4
Association of a homologous recombination deficiency signature with oncologic outcomes in advanced endometrial cancer
20250 citationsauthor #9
Impact of the 2023–2024 chemotherapy shortage on patient care and outcomes in gynecologic oncology: A Society of Gynecologic Oncology survey
20250 citationsauthor #7
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
20251 citationsauthor #16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
202514 citationsauthor #21
A First-In-Human Phase 1 Study Of LY4170156, An Antibody-Drug Conjugate Targeting Folate Receptor α (FRα)-Expressing Advanced Solid Tumors (Trial In Progress)
20250 citationsauthor #4
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
20251 citationsauthor #20
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
20255 citationsauthor #7
Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
20250 citationsauthor #4
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
20250 citationsauthor #19
Mapping The Global Landscape Of Inclusion, Diversity, Equity, And Access In Clinical Trials: Perspectives From Gynaecologic Research Groups
20250 citationsauthor #8
Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey.
20251 citationsauthor #8
Association between race, ethnicity, and mode of mismatch repair mutations on molecular expression and cancer outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
20250 citationsauthor #6
Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
20252 citationsauthor #13
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.
20254 citationsauthor #25
Racial disparity in the utilization of immunotherapy for Food and Drug Administration-approved indications in recurrent endometrial cancer
20250 citationsauthor #22
Current clinical trial screening practices in gynecologic oncology
20250 citationsauthor #10
A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
20251 citationsauthor #5
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer
20240 citationsauthor #14
Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023.
20241 citationsauthor #1
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
202418 citationsauthor #16
Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes.
20240 citationsauthor #8
TP010/#1537 Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
20240 citationsauthor #17
UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer
20243 citationsauthor #5
PT010/#827 DNA damage response alterations within molecular subgroups of endometrial cancer and association with platinum chemotherapy response: an endometrial cancer molecularly targeted therapy consortium study
20240 citationsauthor #11
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
20248 citationsauthor #8
Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
202471 citationsauthor #19
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
20243 citationsauthor #23
Race- associated molecular differences in uterine serous carcinoma
20241 citationsauthor #5
A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer”
20240 citationsauthor #16
Uptake of ovarian cancer genetic testing by disaggregated racial and ethnic subgroups
20240 citationsauthor #3
The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025
20243 citationsauthor #4
37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups
20243 citationsauthor #15
Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
20244 citationsauthor #4
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
20244 citationsauthor #3
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
20245 citationsauthor #2
Treatment patterns and outcomes of endometrial cancer patients with uterine-confined high-risk histology
20240 citationsauthor #3
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
20242 citationsauthor #22
HER2 status, MMR, and p53 expression among endometrial cancer patients
20240 citationsauthor #4
Methodologies for the disaggregation of Asian racial and ethnic subgroups to determine trends in ovarian cancer
20240 citationsauthor #4
HER2 status among a cohort of endometrial cancer patients
20240 citationsauthor #4
Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
20242 citationsauthor #12
Response to Alexandre Andre B A da Costa et al.
20240 citationsauthor #5
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials
20242 citationsauthor #7
Geographic disparities in prescribing patterns of molecularly targeted therapy in advanced and recurrent endometrial cancer
20240 citationsauthor #4
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
202415 citationsauthor #13
Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
20244 citationsauthor #4
#168 UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)
20242 citationsauthor #4
Advanced cervical cancer patients value disease control in addition to overall survival in treatment decision-making: A U.S. patient preference study
20240 citationsauthor #7
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.
20244 citationsauthor #15
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
202462 citationsauthor #14
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
20240 citationsauthor #3
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
20245 citationsauthor #25
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
20241 citationsauthor #2
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
20241 citationsauthor #1
Improving clinical trial enrollment in minority racial and ethnic patients with gynecologic malignancy
20242 citationsauthor #4
A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.
20242 citationsauthor #9
Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists in female patients with a personal history of cancer
20240 citationsauthor #9
Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database
20240 citationsauthor #8
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
202419 citationsauthor #14
Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
202413 citationsauthor #15
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.
20245 citationsauthor #13
Variability of folate receptor alpha expression by race among recurrent ovarian cancer patients
20240 citationsauthor #3
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial.
2024113 citationsauthor #3
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
20240 citationsauthor #1
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
20248 citationsauthor #11
LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
20243 citationsauthor #2
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
20245 citationsauthor #1
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
20245 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT